P/E ratio for Amicus Therapeutics (FOLD)
P/E ratio as of April 2024 (TTM): -16.1
According to Amicus Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.0703. At the end of 2022 the company had a P/E ratio of -14.9.
P/E ratio history for Amicus Therapeutics from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -14.9 | 18.61% |
| 2021 | -12.6 | -41.82% |
| 2020 | -21.6 | 234.55% |
| 2019 | -6.45 | 25.24% |
| 2018 | -5.15 | -34.5% |
| 2017 | -7.86 | 137.33% |
| 2016 | -3.31 | -59.35% |
| 2015 | -8.15 | -8.89% |
| 2014 | -8.95 | 337.79% |
| 2013 | -2.04 | -16.89% |
| 2012 | -2.46 | -7.8% |
| 2011 | -2.67 | 12.91% |
| 2010 | -2.36 | -83.34% |
| 2009 | -14.2 | 209.16% |
| 2008 | -4.59 | 436.07% |
| 2007 | -0.8555 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novo Nordisk NVO | 44.4 | -376.45% | 🇩🇰 Denmark |
 Biogen BIIB | 11.3 | -170.42% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.8 | -173.19% | 🇬🇧 UK |
 Lexicon Pharmaceuticals
LXRX | -2.32 | -85.54% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | -0.6738 | -95.81% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 104 | -747.51% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.